The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer

Trial Profile

The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs Avelumab (Primary) ; Valproic acid (Primary)
  • Indications Anal cancer; Cervical cancer; Hodgkin's disease; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Penile cancer; Squamous cell cancer; Vulvovaginal cancer
  • Focus Therapeutic Use
  • Acronyms LATENT
  • Most Recent Events

    • 02 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 04 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top